| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TFF3 |
| Uniprot No | Q07654 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-80aa |
| 氨基酸序列 | EEYVGLSANQ CAVPAKDRVD CGYPHVTPKE CNNRGCCFDS RIPGVPWCFK PLQEAECTF |
| 预测分子量 | 6.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TFF3(三叶因子3)重组蛋白的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**：*"Production and characterization of recombinant human TFF3"*
**作者**：Kouznetsova I. 等
**摘要**：该研究报道了通过大肠杆菌表达系统成功制备重组人源TFF3蛋白，并验证其生物活性。实验表明，重组TFF3能够促进肠道上皮细胞迁移，且在体外模型中具有黏膜保护作用，为后续疾病治疗研究提供了基础。
---
2. **文献名称**：*"TFF3 interacts with mucins and modulates the barrier function of intestinal epithelial cells in vitro"*
**作者**：Mashimo H. 等
**摘要**：研究利用重组TFF3蛋白探究其与黏蛋白(mucin)的相互作用机制。结果显示，TFF3通过增强黏蛋白网络稳定性，改善肠上皮细胞屏障功能，提示其在炎症性肠病(IBD)等黏膜损伤疾病中的潜在治疗价值。
---
3. **文献名称**：*"Recombinant TFF3 peptide alleviates experimental colitis by suppressing NF-κB signaling"*
**作者**：Thim L. 等
**摘要**：通过动物模型验证重组TFF3的抗炎作用。研究表明，TFF3可通过抑制NF-κB信号通路减轻结肠炎症状，降低促炎细胞因子水平，为开发基于TFF3的炎症性疾病疗法提供了实验依据。
---
**备注**：以上文献为示例性概括，实际引用时建议通过PubMed或Web of Science等平台检索具体文献原文，确保信息准确性。
**Background of TFF3 Recombinant Protein**
Trefoil factor 3 (TFF3), a member of the trefoil factor family, is a small secretory protein primarily expressed in mucous-producing cells of the gastrointestinal tract, respiratory epithelium, and reproductive organs. It plays a critical role in mucosal protection, repair, and restitution through its ability to stabilize mucus layers, enhance cell migration, and suppress apoptosis. Structurally, TFF3 contains a conserved trefoil domain characterized by three disulfide bonds, conferring resistance to proteolytic degradation—a key feature for its function in harsh mucosal environments.
Dysregulation of TFF3 is linked to various pathologies, including inflammatory bowel disease (IBD), cancer, and mucosal injury. Overexpression of TFF3 has been observed in certain cancers (e.g., colorectal, breast), where it may promote tumor progression or act as a biomarker. Conversely, its deficiency correlates with impaired mucosal healing.
Recombinant TFF3 protein is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, to ensure proper folding and post-translational modifications. Purification techniques like affinity chromatography yield high-purity protein for research and therapeutic applications. Studies utilize recombinant TFF3 to explore its mechanisms in epithelial repair, inflammation modulation, and cancer biology. It also holds potential as a therapeutic agent for mucosal damage or as a diagnostic tool.
Overall, TFF3 recombinant protein serves as a vital tool for understanding mucosal homeostasis and developing targeted therapies for gastrointestinal disorders, cancer, and tissue injury.
×
